As of 2025-06-20, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.10) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.32 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -130.0%.
The range of the Relative Valuation is (0.05) - (0.15) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.5x - 8.2x | 5.4x |
| Forward P/E multiples | 2.4x - 8.2x | 5.3x |
| Fair Price | (0.05) - (0.15) | (0.10) |
| Upside | -114.1% - -146.1% | -130.0% |
| Date | P/E |
| 2025-06-05 | -18.28 |
| 2025-06-04 | -18.28 |
| 2025-06-03 | -17.73 |
| 2025-06-02 | -16.62 |
| 2025-05-30 | -16.62 |
| 2025-05-29 | -16.62 |
| 2025-05-27 | -16.62 |
| 2025-05-26 | -16.62 |
| 2025-05-23 | -16.62 |
| 2025-05-22 | -16.07 |
| 2025-05-21 | -16.62 |
| 2025-05-20 | -16.62 |
| 2025-05-16 | -14.96 |
| 2025-05-14 | -15.51 |
| 2025-05-13 | -15.51 |
| 2025-05-08 | -15.51 |
| 2025-05-06 | -15.51 |
| 2025-05-05 | -15.51 |
| 2025-05-01 | -14.41 |
| 2025-04-30 | -14.13 |
| 2025-04-29 | -13.85 |
| 2025-04-25 | -13.85 |
| 2025-04-17 | -13.85 |
| 2025-04-16 | -13.85 |
| 2025-04-15 | -13.57 |
| 2025-04-14 | -13.85 |
| 2025-04-11 | -13.85 |
| 2025-04-10 | -13.85 |
| 2025-04-09 | -14.13 |
| 2025-04-08 | -14.41 |
| 2025-04-07 | -14.13 |
| 2025-04-04 | -14.41 |
| 2025-04-03 | -14.41 |
| 2025-04-02 | -13.85 |
| 2025-04-01 | -14.96 |
| 2025-03-31 | -14.96 |
| 2025-03-26 | -13.85 |
| 2025-03-25 | -14.41 |
| 2025-03-24 | -14.41 |
| 2025-03-21 | -14.13 |
| 2025-03-20 | -13.57 |